SuperworthArrowhead Pharmaceuticals EPS ARWR
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$2.24
- Latest quarter, Q3 FY26
- −$1.36
- Fiscal year 2025
- −$0.07
Arrowhead Pharmaceuticals' earnings per share was −$2.24 over the twelve months to Jun 30, 2026.
In its latest quarter, Q3 FY26, it was −$1.36.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.07 | n/a |
| FY2024 | −$5.01 | n/a |
| FY2023 | −$1.92 | n/a |
| FY2022 | −$1.68 | n/a |
| FY2021 | −$1.36 | n/a |
| FY2020 | −$0.83 | −219% |
| FY2019 | $0.70 | n/a |
| FY2018 | −$0.66 | n/a |
| FY2017 | −$0.46 | n/a |
| FY2016 | −$1.33 | n/a |
| FY2015 | −$1.61 | n/a |
| FY2014 | −$1.23 | n/a |
| FY2013 | −$1.32 | n/a |
| FY2012 | −$1.89 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$1.36 | n/a | −$2.24 | |
| Q2 FY26 | −$0.93 | −134% | −$2.14 | |
| Q1 FY26 | $0.22 | n/a | $1.54 | |
| Q4 FY25 | −$0.17 | n/a | −$0.07 | |
| Q3 FY25 | −$1.26 | n/a | −$1.27 | |
| Q2 FY25 | $2.75 | n/a | −$1.39 | |
| Q1 FY25 | −$1.39 | n/a | −$5.16 | |
| Q4 FY24 | −$1.37 | n/a | −$5.01 | |
| Q3 FY24 | −$1.38 | n/a | −$4.66 | |
| Q2 FY24 | −$1.02 | −327% | −$4.24 | |
| Q1 FY24 | −$1.24 | n/a | −$2.77 | |
| Q4 FY23 | −$1.02 | n/a | −$1.92 |
Against its peers
Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ARWRArrowhead Pharmaceuticals | −$2.24 | |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| Peer median | $1.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Arrowhead Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.